NCT05694741View on ClinicalTrials.gov

A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186

PHASE1TerminatedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

May 10, 2023

Study Completion Date

May 10, 2023

Conditions

Type 2 Diabetes

Interventions

DRUG

AZD0186

Subjects will receive AZD0186 orally.

DRUG

Placebo

Subjects will receive placebo orally.

Trial Locations (1)

91206

Research Site, Glendale

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY